Monopar Therapeutics Inc (MNPR) stock forecast · $431.4M cap
Monopar Therapeutics Inc (MNPR) is a biotechnology company listed on US.
This MNPR forecast page states what the cached financials imply — not a price target and not a guarantee. Monopar Therapeutics Inc outlooks on Lician start from reported revenue and the latest filing, then you decide.
Latest reported MNPR revenue for 2026-06-30 was $0. Net income was -$9.2M. MNPR currently screens at market cap $431.4M.
Period-over-period revenue change is not in cache for MNPR, so this page does not invent a growth rate.
MNPR currently screens at market cap $431.4M. Stretching today's multiple into 2026 without a filing reason is how thin forecast pages get ignored.
When the next MNPR 10-Q or 8-K lands, this outlook should move. Until then the SEC page is the source.
Not a prediction market. For the live quote and the full model, use the MNPR stock page.
Not investment advice.